FDAsafety guidance72% confidence
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (liver cancer) as QL1706.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Hepatocellular Carcinoma
- Sub-indication
- Liver Cancer
Related signal: SBRT Combined with QL1706 Shows Promise in Second-Line Hepatocellular Carcinoma Therapy